Greenwood Genetic Center

GGC First to Enroll in CONNECT-FX Clinical Trial

GREENVILLE, SC – The Greenwood Genetic Center (GGC) is pleased to announce it has been selected as one of approximately 20 sites in the United States, Australia, and New Zealand now enrolling patients in a clinical trial for Fragile X syndrome (FXS). The study will include more than 200 male and female individuals ages three through 17. 

FXS is a genetic condition that causes intellectual disability, behavioral and learning challenges, and is also the most common known single gene cause of autism spectrum disorder. 
 
The newly-initiated study, CONNECT-FX (Clinical Study of Cannabidiol (CBD) in Children and Adolescents with Fragile X), is a 14-week randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of an investigational CBD gel (ZYN002) in children with full mutation FXS. CONNECT-FX is evaluating delivery of the drug through the skin as a potential treatment for some common behavioral symptoms associated with FXS.

Read more here